Sources
Loading...
Additional media
Loading...
DeepNewz, mobile.
People-sourced. AI-powered. Unbiased News.
Alnylam Pharmaceuticals faces a significant stock-moving event with the outcome of the HELIOS-B study, expected by the end of June or early July. Investors are projecting a potential move of around +35% to -30% based on survey results and scientific data related to gene editing technologies.
This week's Biotech Scorecard newsletter: A primer on HELIOS-B, an enormous stock-moving event for Alnylam $ALNY and tangentially $BBIO https://t.co/CCt14Oj8oL Inside: I set the table with background info, define success or failure, and relay some comments from Alnylam CEO…
Adam's Biotech Scorecard: A close look at Alnylam's next big readout https://t.co/4zaa2gBviD
Median -90% Lpa reductions with every 16/24 week dosing. $sln $arwr $amgn $ions #RNAi https://t.co/E987GReLkH